10,908 Results

Phase III INVICTUS study results positive for ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors.-Deciphera Pharmaceuticals.

 Added 1 day ago

Deciphera Pharmaceuticals, Inc. announced positive top-line data from the INVICTUS pivotal Phase III clinical study of ripretinib, a broad-spectrum KIT...

FDA approves Inrebic to treat primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.- Celgene

 Added 2 days ago

Celgene Corporation announced the FDA has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary...

FDA approves Rinvoq to treat moderately to severely active rheumatoid arthritis . AbbVie.

 Added 2 days ago

AbbVie has announced that the FDA has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for...

Leo Pharma A/S acquires rights to develop and market Kyntheum for moderate-to-severe psoriasis outside of Europe.

 Added 2 days ago

Leo Pharma A/S, a global leader in medical dermatology, has announced it has acquired the exclusive rights to develop and...

EMA accepts MAA for filgotinib to treat rheumatoid arthritis .- Gilead Sciences + Galapagos NV

 Added 2 days ago

Gilead Sciences, Inc. and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib , an investigational, oral, selective...

FDA approves Wakix for excessive daytime sleepiness in narcolepsy.- Harmony Biosciences

 Added 2 days ago

The FDA has approved Wakix (pitolisant), from Harmony Biosciences, for the treatment of excessive daytime sleepiness (EDS) in adult patients...

FDA approves Rozlytrek to treat ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors- Genentech/Roche

 Added 2 days ago

Genentech has announced that the FDA has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell...

Novan’s phase III Molluscum pivotal program completes enrollment of B-SIMPLE trials for SB 206.

 Added 3 days ago

Novan, Inc. announced that the Company has recently completed patient recruitment in the Company’s ongoing “B-SIMPLE” (Berdazimer Sodium In Molluscum...

Mallinckrodt announces positive top-line results from its pivotal phase III CONFIRM trial of terlipressin in patients with hepatorenal syndrome Type 1.

 Added 3 days ago

Mallinckrodt Plc announced positive top-line results from its pivotal Phase III CONFIRM clinical study evaluating the efficacy and safety of...

EU approves Imbruvica plus Rituxan for Waldenström's macroglobulinemia.- Janssen Pharma

 Added 3 days ago

Janssen Pharma has announced the European Commission approval of Imbruvica (ibrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia...

Load more